Christen Walters Haygood, MD
Gynecologic Oncology · Jackson, MSNPI 1962639104
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (39.2%), food and beverage and education — rather than concentrated in one kind of arrangement. 30 manufacturers reported payments, led by Merck at 32.4% of the total. Reporting peaked in 2023 at $9,013 and has fallen 50.4% since, to $4,469 in 2025.
Across 198 payments — averaging $138.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$9K
- Pfizer$6K
- Intuitive Surgical$4K
- AstraZeneca$2K
- Seagen Inc.$2K
- GSK$788
- plus $3K from 24 others
Across 43 payments — averaging $8803.55 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$116K
- Seagen Inc.$95K
- AstraZeneca$83K
- Karyopharm Therapeutics Inc.$68K
- Pfizer$11K
- GSK$5K
What the payments were for
- Consulting fees$10,70939%
- Speaking & faculty fees$3,12511%
- Travel & lodging$3,93514%
- Food & beverage$5,35420%
- Education$4,21115%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 46 | $8,854 |
| Pfizer | 6 | $5,967 |
| Intuitive Surgical | 5 | $4,439 |
| AstraZeneca | 15 | $2,299 |
| Seagen Inc. | 3 | $1,644 |
| GSK | 25 | $788 |
| Eisai Inc. | 24 | $744 |
| Provepharm Inc. | 1 | $500 |
| Genmab U.S., Inc. | 15 | $389 |
| AbbVie | 12 | $343 |
| Baxter Healthcare | 3 | $262 |
| Johnson & Johnson | 2 | $222 |
| Immunogen, Inc. | 6 | $141 |
| Davol Inc. | 2 | $133 |
| Clovis Oncology, Inc. | 6 | $92 |
| Pacira Pharmaceuticals Incorporated | 3 | $72 |
| Astellas Pharma US Inc | 3 | $60 |
| Tesaro, Inc. | 3 | $58 |
| Smith+Nephew | 3 | $48 |
| Caris MPI, Inc. | 2 | $36 |
| Vertex | 2 | $36 |
| Conmed Corporation | 1 | $35 |
| Karyopharm Therapeutics Inc. | 1 | $33 |
| Myriad Genetic Laboratories, Inc. | 2 | $30 |
| Coopersurgical, Inc. | 2 | $26 |
| Foundation Medicine, Inc. | 1 | $21 |
| Amgen | 1 | $17 |
| Innovation Technologies Inc | 1 | $16 |
| Therapeuticsmd, Inc. | 1 | $16 |
| Daiichi Sankyo Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few gynecologic oncology providers in Mississippito place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Medroxyprogesterone Acetate | 13 | $66 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 18 | $47 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Jackson
- Rodney RocconiJackson$224K
- Mildred RidgwayJackson$37K
- Donald SeagoJackson$8K
- James MooreJackson$4K
- Michael FinanPascagoula$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.